Clinical trials: in Russia
Prostate Cancer
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Trial name
- CONCORD (NCT07052578)
- Where
- 28 sites in Russia
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Triple Negative Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants…
- Trial name
- NCT03036488
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 193 sites in United States, Australia and 19 more
- Volunteers
- 1,174 people
- Sponsor
- Merck Sharp & Dohme LLC
Sarcopenia, Acute Stroke
Sarcopenia in Acute Ischemic Stroke
The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental…
- Trial name
- NCT07764172
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)
Advanced Non Small Cell Lung Cancer
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
- Trial name
- NCT02143466
- Testing
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- Where
- 42 sites in United States, Canada and 6 more
- Volunteers
- 344 people
- Sponsor
- AstraZeneca
Hypoxemia, Pneumonia, Viral
Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement
Preliminary data support the effect of Nitric Oxide (NO) on improving the oxygenation in mechanically ventilated patients and spontaneously breathing patients with COVID-19.
- Conditions
- Hypoxemia, Pneumonia, Viral, Coronavirus Infection
- Trial name
- NICOR (NCT04476992)
- Testing
- Nitric Oxide-Sessions, Nitric Oxide-Continuous and Sessions
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Non-Small Cell Lung Cancer
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung…
- Trial name
- LIBRETTO-431 (NCT04194944)
- Testing
- Selpercatinib, Carboplatin, Cisplatin
- Where
- 196 sites in Argentina, Australia and 24 more
- Volunteers
- 261 people
- Sponsor
- Eli Lilly and Company
Von Hippel-Lindau Disease, Malignant Neoplasms
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery Solid…
- Trial name
- NCT07405164
- Testing
- Belzutifan, Nivolumab, Lenvatinib
- Where
- 57 sites in United States, Australia and 20 more
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every 8 weeks (Q8W) compared to CAB…
- Trial name
- ATLAS-2M (NCT03299049)
- Testing
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension
- Where
- 119 sites in United States, Argentina and 11 more
- Volunteers
- 1,049 people
- Sponsor
- ViiV Healthcare
Type 2 Diabetes Mellitus, Hypoglycemia
Hypoglycemia Risk Assessment in Elderly and Senile Female Patients With Type 2 Diabetes Mellitus
Hypoglycemia poses a particular danger for elderly patients with type 2 diabetes mellitus (T2DM). According to data, more than 30% of patients aged 60-69 years experience hypoglycemic episodes, and among persons over 85 years…
- Conditions
- Type 2 Diabetes Mellitus, Hypoglycemia, Frailty, Sarcopenia
- Trial name
- HYPOGLYCEMIA16 (NCT07887334)
- Testing
- Comprehensive Geriatric Assessment, Sarcopenia assessment, Laboratory assessment
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Samara State Medical University
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Preconditioning
Personalized Hypoxic-hyperoxic Preconditioning in Elderly People
This study investigates an original protocol of personalized hypoxic-hyperoxic preconditioning utilizing a personalized approach on the basis of cerebral tissue oxygenation assessed with near-infrared spectroscopy.
- Trial name
- NCT07018895
- Testing
- FiO2 reduced by 20% alternating with 34% FiO2
- Where
- Russia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma
Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas
This prospective, single-center, open-label study evaluates a short course of CD20×CD3 bispecific antibody-based holding or bridging therapy before CD19-directed CAR T-cell therapy in adults with relapsed or refractory aggressive…
- Trial name
- NCT07883135
- Testing
- Glofitamab, Epcoritamab, Polatuzumab Vedotin
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- National Research Center for Hematology, Russia
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or…
- Trial name
- PATTERN (NCT03992404)
- Testing
- NT 201
- Where
- 71 sites in United States, Belgium and 13 more
- Volunteers
- 603 people
- Sponsor
- Merz Pharmaceuticals GmbH
Internal Carotid Artery Dolichoarteriopathy, Carotid Artery Tortuosity
Clinical Significance of Internal Carotid Artery Dolichoarteriopathy
This observational study aims to investigate the clinical significance of internal carotid artery dolichoarteriopathy, including tortuosity, kinking, and coiling, and to identify factors associated with cerebral dysfunction and…
- Trial name
- DALISTA (NCT07882875)
- Where
- Russia
- Volunteers
- 560 people
- Sponsor
- Kuban State Medical University
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded…
- Trial name
- NCT04195750
- Testing
- Belzutifan, Everolimus
- Where
- 172 sites in United States, Brazil and 21 more
- Volunteers
- 755 people
- Sponsor
- Merck Sharp & Dohme LLC
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Colitis, Ulcerative
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with…
- Trial name
- UNIFI Jr (NCT04630028)
- Testing
- Ustekinumab Dose Based on BSA and Body Weight
- Where
- 58 sites in United States, Belgium and 7 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Colitis, Ulcerative
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission.
- Trial name
- NCT05076175
- Testing
- Ozanimod
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancies, NSCLC
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit…
- Conditions
- Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer
- Trial name
- NCT05059522
- Testing
- Avelumab, Lorlatanib, Talazoparib
- Where
- 71 sites in United States, Australia and 17 more
- Volunteers
- 77 people
- Sponsor
- Pfizer